<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031650</url>
  </required_header>
  <id_info>
    <org_study_id>Dokuz Eylul Neonatology</org_study_id>
    <nct_id>NCT05031650</nct_id>
  </id_info>
  <brief_title>Open Lung Strategy During Non-Invasive Respiratory Support of Very Preterm Infants in the Delivery Room</brief_title>
  <acronym>OpenCPAP-DR</acronym>
  <official_title>Can Open Lung Strategy During Non-Invasive Respiratory Support of Very Premature Infants in the Delivery Room Reduce Non-Invasive Ventilation Failure Compared With Standard Approach? A Randomised Controlled Multicentric Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dokuz Eylul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dokuz Eylul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The opening and aeration of the lung is critical for a successful transition from fetal to&#xD;
      neonatal life. Early nasal CPAP in the delivery room in spontaneously breathing premature&#xD;
      babies with a gestational age of 30 weeks or less is a standard treatment approach since it&#xD;
      reduces the need for invasive mechanical ventilation and surfactant therapy. In respiratory&#xD;
      distress syndrome (RDS) management, providing optimal lung volumes in the very early period&#xD;
      from the beginning of delivery room approaches probably augments the expected lung protective&#xD;
      effect. Although the benefits of CPAP support are well known, standart CPAP pressures&#xD;
      recommended in the guidelines may not meet the needs of individual babies. Maintaining lung&#xD;
      patency in the delivery room is the main mechanism of action of CPAP and the requirement may&#xD;
      vary individually depending on lung physiology.&#xD;
&#xD;
      In this multicenter randomized controlled study, we aimed to compare the effects of CPAP&#xD;
      therapy applied with a personalized open lung strategy (openCPAP), and standard CPAP therapy&#xD;
      (standardCPAP) on oxygenation, respiratory support need and surfactant treatment requirement&#xD;
      in preterm babies with RDS in the delivery room.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of invasive mechanical ventilation</measure>
    <time_frame>First 72 hours after the intervention</time_frame>
    <description>Need for intubation and mechanical ventilation (MV) Need for intubation and mechanical ventilation (MV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Surfactant therapy</measure>
    <time_frame>First 72 hours after the intervention</time_frame>
    <description>Surfactant therapy requirement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SpO2 at 5th minute</measure>
    <time_frame>5 minute after the delivery</time_frame>
    <description>The oxygen saturation of the blood at 5 th minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SpO2 at 10th minute</measure>
    <time_frame>5 minute after the delivery</time_frame>
    <description>The oxygen saturation of the blood at 10 th minute</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of pneumothorax</measure>
    <time_frame>First 24 hours after the intervention</time_frame>
    <description>Incidence of pneumothorax during intervention and within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence ofIVH (Grade 3-4)</measure>
    <time_frame>First 72 hours after the intervention</time_frame>
    <description>Intraventricular hemorrhage (IVH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilatory support (non-invasive)</measure>
    <time_frame>During first hospitalisation ( an average of 10 weeks)</time_frame>
    <description>Duration of non-invasive MV (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of invasive ventilatory support</measure>
    <time_frame>During first hospitalisation ( an average of 10 weeks)</time_frame>
    <description>Duration of invasive MV ( days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of oxygen (O2)</measure>
    <time_frame>During hospitalisation ( an average of 10 weeks)</time_frame>
    <description>Duration of O2 treatment (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Surfactant treatment</measure>
    <time_frame>During hospitalisation (an average of 10 weeks)</time_frame>
    <description>Mean number of surfactant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia (BPD)</measure>
    <time_frame>At 36th postnatal week or discharge (an average of 10 weeks after intervention ) whichever came first</time_frame>
    <description>Incidence of BPD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>through study completion (an average of 10 weeks)</time_frame>
    <description>Death or composite outcome death/BPD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Respiratory Distress Syndrome in Premature Infant</condition>
  <condition>Non-invasive Ventilation</condition>
  <condition>Lung Injury</condition>
  <arm_group>
    <arm_group_label>openCPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediately after birth, early nCPAP will be started with a nasal mask with a T-piece resuscitator with 8 cm H2O pressure and 0.30 fiO2. The heart rate (HR) and preductal saturation (SpO2) will be evaluated every 30 seconds. Individually, the following steps will be done according to the situation:&#xD;
If the HR &gt; 120 / min and SpO2 not measured yet or be in the target range: The pressure will be continue as 8 cmH2O.&#xD;
If the HR between 100-120 but SpO2 below the target range or not measured yet : First the pressure will be increased to 10 cm H2O; than fiO2 will be increased gradually if the patient will not respond to 10 cmH2O pressure. Pressure will be reduced to 8 cmH2O if the HR remains&gt; 120 / min and oxygen requirement &lt;0.30 for more than 60 seconds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standardCPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediately after birth, early nCPAP will be started with a nasal mask with T-piece resuscitator at 6 cmH2O pressure and 0.30 fiO2. HR and preductal saturation will be evaluated every 30 seconds. The following steps will be performed according to the situation:&#xD;
If the HR &gt; 120 / min and SpO2 be in the target range or not measurable yet: The pressure will be continue as 6 cmH2O.&#xD;
If the HR between 100-120 but SpO2 below the target range or not measured yet : The pressure will increased up to 8 cm H2O. FiO2 will be increased gradually if the patient will not respond to 8 cmH2O pressure. Pressure will be reduced to 6 cmH2O if the HR remains&gt; 120 / min and oxygen requirement &lt;0.30 for more than 60 seconds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>openCPAP</intervention_name>
    <description>Randomized to : Individualized high level CPAP between 8-10 cmH2O pressure</description>
    <arm_group_label>openCPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standardCPAP</intervention_name>
    <description>Randomized to : Standard level CPAP between 6-8 cmH2O pressure</description>
    <arm_group_label>standardCPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants born before 30 completed weeks of gestation and received early nCPAP&#xD;
             immediately after birth in delivery room&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requirement of surfactant or endotracheal intubation or positive pressure ventilation&#xD;
             before the completion of interventions&#xD;
&#xD;
          -  Major congenital anomaly&#xD;
&#xD;
          -  Transportation to another hospital&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Minutes</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hasan Ozkan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz Eylül University- Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nuray Duman, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Dokuz Eylül University- Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Funda Tuzun, Assoc.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz Eylül University- Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuray Duman, Prof.</last_name>
    <phone>90 4121220</phone>
    <email>nduman68@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Funda Tuzun, Assoc. Prof.</last_name>
    <phone>90 4126269</phone>
    <email>fundatuzun@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Etlik Zubeyde Hanım Maternity and Children Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University</name>
      <address>
        <city>İzmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuray Duman, Prof.</last_name>
      <phone>05332601440</phone>
      <email>nduman68@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Funda Tuzun, Asoc. Prof.</last_name>
      <phone>05055678490</phone>
      <email>fundatuzun@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hasan Ozkan, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Funda Tuzun, Asoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmet Yağmur Baş, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nihal Demir, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dokuz Eylul University</investigator_affiliation>
    <investigator_full_name>Funda Tuzun</investigator_full_name>
    <investigator_title>Assoc. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>nasal CPAP</keyword>
  <keyword>delivery room</keyword>
  <keyword>open lung strategy</keyword>
  <keyword>PEEP</keyword>
  <keyword>Respiratory Distress Syndrome</keyword>
  <keyword>Individualised ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

